Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021

Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high...

Descripción completa

Detalles Bibliográficos
Autores principales: Subbarao, Sathyavani, Warrener, Lenesha A, Hoschler, Katja, Perry, Keith R, Shute, Justin, Whitaker, Heather, O’Brien, Michelle, Baawuah, Frances, Moss, Paul, Parry, Helen, Ladhani, Shamez N, Ramsay, Mary E, Brown, Kevin E, Amirthalingam, Gayatri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995559/
https://www.ncbi.nlm.nih.gov/pubmed/33769252
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.12.2100329
_version_ 1783669941624373248
author Subbarao, Sathyavani
Warrener, Lenesha A
Hoschler, Katja
Perry, Keith R
Shute, Justin
Whitaker, Heather
O’Brien, Michelle
Baawuah, Frances
Moss, Paul
Parry, Helen
Ladhani, Shamez N
Ramsay, Mary E
Brown, Kevin E
Amirthalingam, Gayatri
author_facet Subbarao, Sathyavani
Warrener, Lenesha A
Hoschler, Katja
Perry, Keith R
Shute, Justin
Whitaker, Heather
O’Brien, Michelle
Baawuah, Frances
Moss, Paul
Parry, Helen
Ladhani, Shamez N
Ramsay, Mary E
Brown, Kevin E
Amirthalingam, Gayatri
author_sort Subbarao, Sathyavani
collection PubMed
description Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom’s approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.
format Online
Article
Text
id pubmed-7995559
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-79955592021-04-01 Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021 Subbarao, Sathyavani Warrener, Lenesha A Hoschler, Katja Perry, Keith R Shute, Justin Whitaker, Heather O’Brien, Michelle Baawuah, Frances Moss, Paul Parry, Helen Ladhani, Shamez N Ramsay, Mary E Brown, Kevin E Amirthalingam, Gayatri Euro Surveill Rapid Communication Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom’s approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine. European Centre for Disease Prevention and Control (ECDC) 2021-03-25 /pmc/articles/PMC7995559/ /pubmed/33769252 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.12.2100329 Text en This article is copyright of the authors or their affiliated institutions, 2021. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Subbarao, Sathyavani
Warrener, Lenesha A
Hoschler, Katja
Perry, Keith R
Shute, Justin
Whitaker, Heather
O’Brien, Michelle
Baawuah, Frances
Moss, Paul
Parry, Helen
Ladhani, Shamez N
Ramsay, Mary E
Brown, Kevin E
Amirthalingam, Gayatri
Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021
title Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021
title_full Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021
title_fullStr Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021
title_full_unstemmed Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021
title_short Robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021
title_sort robust antibody responses in 70–80-year-olds 3 weeks after the first or second doses of pfizer/biontech covid-19 vaccine, united kingdom, january to february 2021
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995559/
https://www.ncbi.nlm.nih.gov/pubmed/33769252
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.12.2100329
work_keys_str_mv AT subbaraosathyavani robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT warrenerleneshaa robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT hoschlerkatja robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT perrykeithr robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT shutejustin robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT whitakerheather robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT obrienmichelle robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT baawuahfrances robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT mosspaul robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT parryhelen robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT ladhanishamezn robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT ramsaymarye robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT brownkevine robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021
AT amirthalingamgayatri robustantibodyresponsesin7080yearolds3weeksafterthefirstorseconddosesofpfizerbiontechcovid19vaccineunitedkingdomjanuarytofebruary2021

Ejemplares similares